A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia

Agostino Cortelezzi, Maria Cristina Pasquini, Barbara Sarina, Giambattista Bertani, Federica Grifoni, Mariangela Colombi, Giorgio Lambertenghi Deliliers

Research output: Contribution to journalArticle


Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.

Original languageEnglish
Pages (from-to)410-412
Number of pages3
Issue number3
Publication statusPublished - Mar 2005



  • Alemtuzumab
  • Autoimmune hemolytic anemia
  • B-CLL
  • Complete response
  • HBV
  • Overall response
  • Safety

ASJC Scopus subject areas

  • Hematology

Cite this